CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
OcellO B.V. is enhancing its drug screening services by developing 3D organoid cultures that combine cancer and immune cells. This innovative approach aims to improve the selection process for immuno-modulating cancer drugs, addressing a significant need in cancer treatment development.
OcellO B.V., a Dutch SME, is recruiting an Immuno-Oncology Innovation Associate to support the diversification of its portfolio of innovative services.
OcellO is a contract research organization (CRO) that delivers supreme in vitro screening tools for drug developers.
The SME has a number of high-throughput screening tools on the market, all of which are based on its proprietary 3D cell culture technique with concomitant imaging and analyses tools.
Currently, OcellO is growing so-called ‘organoi…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
